Peptide-loaded DC vaccines selectively targeting tumor-associated antigens (TAAs) such as mucin 1 (MUC1), Wilms’ tumor gene 1 (WT1) and mutant K-RAS also enhance more cytotoxic lymphocyte response. This evidence concerns the gene MUC1 and neoplasm.